Market
Will there be changes in CEO or CFO roles at Senti Biosciences by the end of 2025?
3
Resolution / Starting Odds
CEO change • 25%
CFO change • 25%
Both CEO and CFO change • 25%
No change • 25%
Senti Biosciences official announcements or leadership news
Story
Senti Biosciences Reports Positive SENTI-202 Trial Data, Secures $37.6M Financing, and Sees 139.8% Stock Increase
Dec 2, 2024, 01:20 PM
Senti Biosciences, Inc. announced positive initial clinical data from its Phase 1 trial of SENTI-202, a logic-gated, selective CD33/FLT3-targeting CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial showed promising results, with two out of three patients achieving minimal residual disease (MRD)-negative complete remission (CR) and a generally favorable safety profile. Additionally, the company secured $37.6 million in an oversubscribed private placement equity financing and appointed Fran Schulz to its Board of Directors as a new member and audit chair. These developments have led to a significant pre-market stock price increase of 139.8%.
View original story
Similar markets
Other leadership changes • 25%
CEO change • 25%
Board reshuffle • 25%
No significant changes • 25%
No changes • 25%
CISO change • 25%
COO change • 25%
CEO change • 25%
Temporary appointment • 25%
External hire • 25%
Internal promotion • 25%
No appointment by deadline • 25%
CMO • 25%
Other • 25%
Chair of the Board • 25%
CFO • 25%
External hire from a non-tech company • 25%
Interim CFO remains in position • 25%
External hire from another tech company • 25%
Internal promotion • 25%
Other • 25%
External Hire • 25%
Ansys Executive • 25%
Current CEO • 25%
Other • 25%
Masayoshi Son • 25%
Sam Altman • 25%
Larry Ellison • 25%
Interim leadership • 34%
Existing leadership retained • 33%
New CEO appointed • 33%
No major changes • 25%
Elon Musk steps down as CEO • 25%
Other executive changes • 25%
New CFO appointed • 25%